• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

By: Exagen Inc. via GlobeNewswire
July 15, 2025 at 16:05 PM EDT

CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).

Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

A replay of the conference call will be available until Tuesday, August 12, 2025. Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13753132. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, visit Exagen.com or follow @ExagenInc on X.

Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525


Primary Logo

More News

View More
Domino’s Delivers Another Discounted Entry for Income Investors
July 21, 2025
Via MarketBeat
Tickers DPZ
TSLA Earnings Week: Can Tesla Break Through $350?
July 21, 2025
Via MarketBeat
Tickers TSLA
Goldman, Morgan Stanley, & BofA: Diverging Paths After Earnings
July 21, 2025
Via MarketBeat
Tickers BAC GS MS
Build Stability and Income With 3 Overlooked Dividend Leaders
July 21, 2025
Via MarketBeat
Tickers EPD JNJ KO OKE
Kinder Morgan: At the Hotspot of the Natural Gas Revolution
July 21, 2025
Via MarketBeat
Topics Energy
Tickers KMI
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap